South San Francisco Newswire

Comprehensive Real-Time News Feed for South San Francisco, CA.

Results 1 - 20 of 50 for "u:pr-inside.com" in South San Francisco, CA

  1. Cytokinetics Joins Global Movement to Raise Awareness for Rare DiseasesRead the original story

    Friday Feb 27 | PR-inside.com

    SOUTH SAN FRANCISCO, CA, February 27, 2015 - Cytokinetics, Incorporated announced today that it is joining forces on February 28 with patients and health care advocates in the United States and globally to raise awareness for Rare Disease Day . Rare Disease Day is dedicated to elevating public understanding of rare diseases and calling attention to the special challenges faced by patients with rare diseases and the support community around them.

    Comment?

  2. Cytokinetics Announces Publication of Preclinical Data Relating to...Read the original story

    Thursday Feb 26 | PR-inside.com

    Manuscript Supports Rationale for Development of CK-2127107 in Diseases Associated with Muscle Weakness and Fatigue South San Francisco, CA, February 26, 2015 - Cytokinetics, Incorporated announced the publication of a manuscript relating to its fast skeletal muscle troponin activator CK-2127107 in The Journal of Pharmacology and Experimental Therapeutics. This publication relates to a preclinical evaluation of CK-2127107 in a rat model of heart failure that demonstrated CK-2127107 was associated with increased exercise performance in this model.

    Comment?

  3. Cytokinetics to Present at Healthcare Conferences in MarchRead the original story

    Tuesday Feb 24 | PR-inside.com

    South San Francisco, CA, February 24, 2015 - Cytokinetics, Incorporated announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following healthcare conferences: Cowen and Company 35 Annual Health Care Conference Date: Tuesday, March 3, 2015 Time: 11:20 AM Eastern Time Location: Boston Marriott Copley Place Hotel, Boston, MA 27 Annual ROTH Conference Date: Monday, March 9, 2015 Time: 8:30 AM Pacific Time Location: Ritz-Carlton, Laguna Nigel, Dana Point, CA Interested parties may access the live audio of this presentation by visiting the Investor Relations section of the Cytokinetics website at www.cytokinetics.com.

    Comment?

  4. Portola Pharmaceuticals, Inc. (PTLA) - Pharmaceuticals & Healthcare - ...Read the original story

    Friday Feb 20 | PR-inside.com

    It undertakes the discovery and development of innovative therapeutics for the treatment of cardiovascular, inflammation, and oncology indications. The company's product portfolio includes Betrixaban, Andexanet Alfa , PRT2607, and PRT2070.

    Comment?

  5. Market Report, "Nodality, Inc. - Pharmaceuticals & Healthcare - Deals ...Read the original story

    Thursday Feb 19 | PR-inside.com

    Nodality, Inc. is a biotechnology company. The company discovers and develops personal diagnostics characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells from individual patients.

    Comment?

  6. Cytokinetics, Incorporated Reports Fourth Quarter 2014 Financial ResultsRead the original story

    Thursday Feb 12 | PR-inside.com

    Ongoing Regulatory Interactions in US and Europe Inform Progression of Tirasemtiv to Phase III COSMIC-HF Nears Completion of Enrollment with Results Expected Later This Year Company Exceeded Financial Guidance in 2014 and Provides Milestones and Financial Guidance for 2015 SOUTH SAN FRANCISCO, CA, February 12, 2015 - Cytokinetics, Incorporated reported total research and development revenues for the fourth quarter of 2014 were $21.8 million, compared to $24.3 million during the same period in 2013. The net income for the fourth quarter was $8.4 million, or $0.23 per basic and diluted share.

    Comment?

  7. Recent Study: Poniard Pharmaceuticals, Inc. (PARD) - Pharmaceuticals...Read the original story

    Thursday Feb 12 | PR-inside.com

    The company focused on developing picoplatin product, which is a new generation platinum based cancer therapy. Picoplatin is designed to overcome platinum resistance in the treatment of solid tumors.

    Comment?

  8. Now Available: Titan Pharmaceuticals, Inc. (TTNP) - Financial and Strategic SWOT Analysis ReviewRead the original story

    Wednesday Feb 11 | PR-inside.com

    The company develops therapeutics for the treatment of central nervous system disorders. Its products include probuphine used for the treatment of opioid addiction, iloperidone used for the treatment of schizophrenia and related psychotic disorders.

    Comment?

  9. New Market Report: Talon Therapeutics, Inc. (TLON) - Pharmaceuticals...Read the original story

    Wednesday Feb 11 | PR-inside.com

    Talon Therapeutics, Inc. is a biopharmaceutical company. It researches, develops and commercializes products for cancer.

    Comment?

  10. Fluidigm Corporation - Pharmaceuticals & Healthcare - Deals and...Read the original story

    Monday Feb 2 | PR-inside.com

    The company manufactures and markets microfluidic-based chips and instrumentation for biological research. Its products and systems include biomark HD system, C1 system, EP1 system, access array system, chips and kits, DELTagene assays, SNPtype assays, target-specific primers and software.

    Comment?

  11. Cytokinetics to Announce Fourth Quarter Results on February 12, 2015Read the original story

    Jan 29, 2015 | PR-inside.com

    South San Francisco, CA., January 29, 2015, - Cytokinetics, Incorporated announced today that it is scheduled to report fourth quarter results on Thursday, February 12, 2015 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

    Comment?

  12. Market Report, "Poniard Pharmaceuticals, Inc. (PARD) - Financial and...Read the original story

    Jan 27, 2015 | PR-inside.com

    The company focused on developing picoplatin product, which is a new generation platinum based cancer therapy. Picoplatin is designed to overcome platinum resistance in the treatment of solid tumors.

    Comment?

  13. "Theravance, Inc. (THRX) - Financial and Strategic SWOT Analysis Review" PublishedRead the original story

    Jan 17, 2015 | PR-inside.com

    Theravance, Inc. is a biopharmaceutical company. The company discovers, develops and commercializes small molecule medicines.

    Comment?

  14. New Report Available: Sunesis Pharmaceuticals, Inc. - Strategy and SWOT ReportRead the original story

    Jan 16, 2015 | PR-inside.com

    The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360deg view of the company.

    Comment?

  15. Rigel Pharmaceuticals, Inc. - Strategy and SWOT Report - New Study ReleasedRead the original story

    Jan 16, 2015 | PR-inside.com

    Rigel Pharmaceuticals, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360deg view of the company.

    Comment?

  16. Market Report, "AvidBiotics Corp. - Pharmaceuticals & Healthcare -...Read the original story

    Jan 4, 2015 | PR-inside.com

    The company develops non-antibody proteins which targets bacteria, viruses or cancer cells for human therapeutic and prophylactic uses. It develops human health care, food safety, and other products.

    Comment?

  17. New Report Available: Rigel Pharmaceuticals, Inc. (RIGL) -...Read the original story

    Jan 3, 2015 | PR-inside.com

    It discovers and develops small-molecule drugs to treat inflammatory and autoimmune diseases; and muscle disorders. The company's product pipeline comprises fostamatinib in Phase III clinical trials for the treatment of Immune Thrombocytopenic Purpura and Phase II for IgA Nephropathy ; R348 in Phase II clinical trials for the treatment of keratoconjunctivitis sicca and dry eye in patients with ocular graft-versus-host disease ; R118 in Phase I clinical trial for the treatment of intermittent claudication associated with peripheral artery disease; and two oncology products in Phase I clinical trials that are being developed with partners, BerGenBio AS and Daiichi Sankyo, respectively.

    Comment?

  18. Hyperion Therapeutics, Inc. (HPTX) - Pharmaceuticals & Healthcare -...Read the original story

    Dec 30, 2014 | PR-inside.com

    It develops and commercializes novel drugs for the treatment of orphan diseases and hepatology disorders. Ravicti, the company's first approved product is indicated for use as a nitrogen-binding agent in adult and paediatric patients aged above two years suffering with urea cycle disorders and those who cannot be treated by dietary protein restriction and amino acid supplementation alone.

    Comment?

  19. Just Published: "Exelixis, Inc. (EXEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile"Read the original story

    Dec 28, 2014 | PR-inside.com

    Exelixis, Inc. is a biotechnology company. It focuses on the development of pharmaceutical products for treatment of cancer and other life threatening diseases.

    Comment?

  20. "NGM Biopharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile" PublishedRead the original story

    Dec 28, 2014 | PR-inside.com

    The company manufactures pharmaceutical ingredients and intermediate products that are used in animal and human health. Its products include finished dosage forms, diminazene aceturate granules and homidium chloride tablets.

    Comment?

South San Francisco Job Listings
View or post South San Francisco job listings on Topix.
South San Francisco Real Estate
News, listings, and foreclosures in South San Francisco from Topix.
South San Francisco Mortgages
Find mortgage rates in South San Francisco on Topix.